> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher Awarded to AveXis
- URL: https://www.fdaweb.com/priority-review-voucher-awarded-to-avexis/
- Published: 2019-06-21T12:00:00.000Z
- Updated: 2026-09-15T01:34:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144396

*Federal Register* notice: FDA has announced that it issued a priority review voucher to AveXis for its rare pediatric disease product Zolgensma (onasemnogene abeparvovec-xioi), indicated for treating pediatric patients less than two years of age with spinal muscular atrophy with biallelic mutations in the survival motor neuron 1 gene. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-13356.pdf?ref=fdaweb.com).